Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?
出版年份 2017 全文链接
标题
Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?
作者
关键词
-
出版物
Frontiers in Immunology
Volume 8, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2017-10-04
DOI
10.3389/fimmu.2017.01245
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Immunoglobulin A: magic bullet or Trojan horse?
- (2017) Marieke H. Heineke et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody–associated vasculitis
- (2017) Federico Alberici et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- DC subset–specific induction of T cell responses upon antigen uptake via Fcγ receptors in vivo
- (2017) Christian H.K. Lehmann et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms
- (2017) Kirstie L. S. Cleary et al. JOURNAL OF IMMUNOLOGY
- Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile
- (2017) Christine W. Bruggeman et al. JOURNAL OF IMMUNOLOGY
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- (2017) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Human IgG3 with extended half-life does not improve Fc-gamma receptor-mediated cancer antibody therapies in mice
- (2017) Rens Braster et al. PLoS One
- Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples
- (2017) Venkat Reddy et al. RHEUMATOLOGY
- Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo
- (2017) Bingyu Li et al. Oncotarget
- Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma
- (2017) Allison Rosenthal Current Hematologic Malignancy Reports
- Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds
- (2017) Hongyan Liu et al. Frontiers in Immunology
- Idelalisib for treatment of B-cell malignancies
- (2016) B. Do et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis
- (2016) Liang Liang et al. ANNALS OF HEMATOLOGY
- OP0182 Prevention of Rheumatoid Arthritis by B Cell Directed Therapy in The Earliest Phase of The Disease: The Prairi Study
- (2016) D. Gerlag et al. ANNALS OF THE RHEUMATIC DISEASES
- Diverse macrophages polarization in tumor microenvironment
- (2016) Inmoo Rhee ARCHIVES OF PHARMACAL RESEARCH
- Trastuzumab in the Treatment of Breast Cancer
- (2016) Sofia Maximiano et al. BIODRUGS
- Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
- (2016) B. L. Lampson et al. BLOOD
- Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial
- (2016) Jeff P. Sharman et al. BRITISH JOURNAL OF HAEMATOLOGY
- CTLA-4 Limits Anti-CD20–Mediated Tumor Regression
- (2016) Zhenhua Ren et al. CLINICAL CANCER RESEARCH
- Fc Engineering to Improve the Function of Therapeutic Antibodies
- (2016) Futa Mimoto et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Olaratumab: First Global Approval
- (2016) Matt Shirley DRUGS
- Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma
- (2016) Jacqueline C Barrientos Future Oncology
- Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study
- (2016) Gilles Salles et al. HAEMATOLOGICA
- Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody
- (2016) Di Zhang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells
- (2016) Patrick J. Engelberts et al. JOURNAL OF IMMUNOLOGY
- Cutting Edge: IgE Plays an Active Role in Tumor Immunosurveillance in Mice
- (2016) Elisa A. Nigro et al. JOURNAL OF IMMUNOLOGY
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
- (2016) Sagar Lonial et al. LANCET
- Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
- (2016) William D Tap et al. LANCET
- Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial
- (2016) Michael L Wang et al. LANCET ONCOLOGY
- Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
- (2016) Asher Chanan-Khan et al. LANCET ONCOLOGY
- PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis
- (2016) M J Carter et al. LEUKEMIA
- Antibodies to watch in 2017
- (2016) Janice M. Reichert mAbs
- Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors
- (2016) Daniel F. Ortiz et al. Science Translational Medicine
- The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia
- (2016) Jennifer R. Brown SEMINARS IN ONCOLOGY
- Dinutuximab: A Review in High-Risk Neuroblastoma
- (2016) Sheridan M. Hoy Targeted Oncology
- A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface
- (2016) Rob N. de Jong et al. PLOS BIOLOGY
- Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study
- (2016) Gilles Salles et al. HAEMATOLOGICA
- Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
- (2015) J. C. Byrd et al. BLOOD
- Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo
- (2015) Ali Roghanian et al. CANCER CELL
- The Tumor Microenvironment Regulates CD19 and CD20 Immunotherapy for Lymphoma
- (2015) Jacquelyn M. Lykken et al. CANCER JOURNAL
- Antibody-Dependent Phagocytosis of Tumor Cells by Macrophages: A Potent Effector Mechanism of Monoclonal Antibody Therapy of Cancer
- (2015) N. Gul et al. CANCER RESEARCH
- Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect
- (2015) David J. DiLillo et al. CELL
- Dinutuximab: First Global Approval
- (2015) Sohita Dhillon DRUGS
- A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas
- (2015) Pierre Feugier Future Oncology
- Suppression of Fcγ-Receptor-Mediated Antibody Effector Function during Persistent Viral Infection
- (2015) Douglas H. Yamada et al. IMMUNITY
- Antibody Effector Functions Mediated by Fcγ-Receptors Are Compromised during Persistent Viral Infection
- (2015) Andreas Wieland et al. IMMUNITY
- Structural analysis of Fc/FcγR complexes: a blueprint for antibody design
- (2015) Jose M. M. Caaveiro et al. IMMUNOLOGICAL REVIEWS
- Fcγ receptors: genetic variation, function, and disease
- (2015) Chantal E. Hargreaves et al. IMMUNOLOGICAL REVIEWS
- Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fc Receptors
- (2015) A. L. Tutt et al. JOURNAL OF IMMUNOLOGY
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
- (2015) Max S Topp et al. LANCET ONCOLOGY
- Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding
- (2015) M Jack Borrok et al. mAbs
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies
- (2015) Liping L. Sun et al. Science Translational Medicine
- FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities
- (2015) Falk Nimmerjahn et al. TRENDS IN IMMUNOLOGY
- A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys
- (2015) Eric J. Smith et al. Scientific Reports
- Internalization of Rituximab and the Efficiency of B Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus
- (2015) Venkat Reddy et al. Arthritis & Rheumatology
- Complement System Part I – Molecular Mechanisms of Activation and Regulation
- (2015) Nicolas S. Merle et al. Frontiers in Immunology
- Fc -receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments
- (2014) R. P. Taylor et al. BLOOD
- Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies
- (2014) Friedhelm R. Schuster et al. BRITISH JOURNAL OF HAEMATOLOGY
- IgGA: A “Cross-Isotype” Engineered Human Fc Antibody Domain that Displays Both IgG-like and IgA-like Effector Functions
- (2014) William Kelton et al. CHEMISTRY & BIOLOGY
- Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy
- (2014) F. D. Roit et al. HAEMATOLOGICA
- OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy
- (2014) Yannick Bulliard et al. IMMUNOLOGY AND CELL BIOLOGY
- Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study
- (2014) Anas Younes et al. LANCET ONCOLOGY
- Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
- (2014) Ian E Krop et al. LANCET ONCOLOGY
- Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study
- (2014) Jan A Burger et al. LANCET ONCOLOGY
- Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial
- (2014) Nathan H Fowler et al. LANCET ONCOLOGY
- Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia
- (2014) Carolyn M Cheney et al. mAbs
- Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody
- (2014) Céline Monnet et al. mAbs
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preclinical Systemic Lupus Erythematosus
- (2014) Julie M. Robertson et al. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
- (2014) C. A. Diebolder et al. SCIENCE
- The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study
- (2013) Luca Quartuccio et al. ANNALS OF THE RHEUMATIC DISEASES
- A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults
- (2013) Gabriel J. Robbie et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Neutrophils mediate antibody-induced antitumor effects in mice
- (2013) M. Albanesi et al. BLOOD
- Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab
- (2013) J. Golay et al. BLOOD
- Novel antibodies targeting immune regulatory checkpoints for cancer therapy
- (2013) Chern Siang Lee et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab
- (2013) Eleanor J. Cheadle et al. BRITISH JOURNAL OF HAEMATOLOGY
- An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels
- (2013) Thies Rösner et al. BRITISH JOURNAL OF HAEMATOLOGY
- High levels of CD20 expression predict good prognosis in chronic lymphocytic leukemia
- (2013) Cheng Fang et al. CANCER SCIENCE
- The mechanism of anti-CD20–mediated B cell depletion revealed by intravital imaging
- (2013) Fabricio Montalvao et al. JOURNAL OF CLINICAL INVESTIGATION
- Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
- (2013) Yannick Bulliard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Reduced T-Dependent Humoral Immunity in CD20-Deficient Mice
- (2013) D. E. D. Morsy et al. JOURNAL OF IMMUNOLOGY
- Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial
- (2013) Raymund Buhmann et al. Journal of Translational Medicine
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
- (2013) Jason R Westin et al. LANCET ONCOLOGY
- Myeloid cells as effector cells for monoclonal antibody therapy of cancer
- (2013) Rens Braster et al. METHODS
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Antitumor activities of agonistic anti-TNFR antibodies require differential Fc RIIB coengagement in vivo
- (2013) F. Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Engineered antibody Fc variant with selectively enhanced Fc RIIb binding over both Fc RIIaR131 and Fc RIIaH131
- (2013) F. Mimoto et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Humoral Pattern Recognition and the Complement System
- (2013) S. E. Degn et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies
- (2013) Maria J Leandro ARTHRITIS RESEARCH & THERAPY
- Effective Phagocytosis of Low Her2 Tumor Cell Lines with Engineered, Aglycosylated IgG Displaying High FcγRIIa Affinity and Selectivity
- (2012) Sang Taek Jung et al. ACS Chemical Biology
- Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study
- (2012) Brad H. Rovin et al. ARTHRITIS AND RHEUMATISM
- Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms
- (2012) H. Ghesquieres et al. BLOOD
- Using the allergic immune system to target cancer: activity of IgE antibodies specific for human CD20 and MUC1
- (2012) Pearline Zhaoying Teo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma
- (2012) Andres Forero-Torres et al. CLINICAL CANCER RESEARCH
- Analysis of Fc Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients
- (2012) S. A. Hurvitz et al. CLINICAL CANCER RESEARCH
- Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells
- (2012) V. Pascal et al. HAEMATOLOGICA
- Homozygous A polymorphism of the complement C1qA276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP
- (2012) Xuan Jin et al. Journal of Hematology & Oncology
- The novel tribody [(CD20)2xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells
- (2012) P Glorius et al. LEUKEMIA
- Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function
- (2012) D J DiLillo et al. LEUKEMIA
- The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
- (2012) Peter D Senter et al. NATURE BIOTECHNOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity
- (2012) Henrik E Mei et al. ARTHRITIS RESEARCH & THERAPY
- A review of the history, properties, and use of the immunomodulatory compound lenalidomide
- (2011) Jerome B. Zeldis et al. Annals of the New York Academy of Sciences
- The Cell Biology of Phagocytosis
- (2011) Ronald S. Flannagan et al. Annual Review of Pathology-Mechanisms of Disease
- B cell biomarkers of rituximab responses in systemic lupus erythematosus
- (2011) Edward M. Vital et al. ARTHRITIS AND RHEUMATISM
- CD20 antibodies: doing the time warp
- (2011) M. S. Cragg BLOOD
- Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
- (2011) W. Alduaij et al. BLOOD
- Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies
- (2011) G. Niederfellner et al. BLOOD
- Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy
- (2011) S. H. Lim et al. BLOOD
- An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells
- (2011) Nicholas S. Wilson et al. CANCER CELL
- The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone
- (2011) Joseph M. Tuscano et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tumor-Associated Neutrophils: New Targets for Cancer Therapy
- (2011) A. D. Gregory et al. CANCER RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- An Acquired Defect in IgG-Dependent Phagocytosis Explains the Impairment in Antibody-Mediated Cellular Depletion in Lupus
- (2011) A. Ahuja et al. JOURNAL OF IMMUNOLOGY
- Interaction with Fc RIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody
- (2011) A. L. White et al. JOURNAL OF IMMUNOLOGY
- Neonatal Fc receptor and IgG-based therapeutics
- (2011) Timothy T. Kuo et al. mAbs
- STING is a direct innate immune sensor of cyclic di-GMP
- (2011) Dara L. Burdette et al. NATURE
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential
- (2011) Nigel M. Stapleton et al. Nature Communications
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
- (2010) E. Mossner et al. BLOOD
- Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response
- (2010) R. Abes et al. BLOOD
- Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
- (2010) B. Coiffier et al. BLOOD
- CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
- (2010) B. J. Lannutti et al. BLOOD
- Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells
- (2010) Y. Iwata et al. BLOOD
- Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
- (2010) S. A. Beers et al. BLOOD
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
- (2010) SaeGwang Park et al. CANCER CELL
- Construction and Characterization of a Bispecific Anti-CD20 Antibody with Potent Antitumor Activity against B-Cell Lymphoma
- (2010) B. Li et al. CANCER RESEARCH
- In vivo Cytotoxicity of Type I CD20 Antibodies Critically Depends on Fc Receptor ITAM Signaling
- (2010) S. de Haij et al. CANCER RESEARCH
- Rituximab
- (2010) Gillian M. Keating DRUGS
- Ofatumumab, a Novel Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies
- (2010) Bruce D. Cheson JOURNAL OF CLINICAL ONCOLOGY
- In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
- (2010) Joshua D. Brody et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of IgG1 variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: Comparison of soluble receptor-based and cell-based binding assays
- (2010) Yanmei Lu et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies
- (2010) M Le Garff-Tavernier et al. LEUKEMIA
- Enhanced antibody half-life improves in vivo activity
- (2010) Jonathan Zalevsky et al. NATURE BIOTECHNOLOGY
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rituximab: Mechanism of Action
- (2010) George J. Weiner SEMINARS IN HEMATOLOGY
- CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies
- (2010) Stephen A. Beers et al. SEMINARS IN HEMATOLOGY
- Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
- (2009) Joan T. Merrill et al. ARTHRITIS AND RHEUMATISM
- Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab
- (2009) S. P. Hilchey et al. BLOOD
- Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model
- (2009) S.-Y. Wang et al. BLOOD
- Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma
- (2009) Jonathan W. Friedberg et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
- (2009) S. M. Ansell et al. CLINICAL CANCER RESEARCH
- Anti-CD20 monoclonal antibodies: historical and future perspectives
- (2009) S. H. Lim et al. HAEMATOLOGICA
- CD20 deficiency in humans results in impaired T cell–independent antibody responses
- (2009) Taco W. Kuijpers et al. JOURNAL OF CLINICAL INVESTIGATION
- Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage
- (2009) Tanja Schneider-Merck et al. JOURNAL OF IMMUNOLOGY
- Nonfucosylated anti-CD20 antibody potentially induces apoptosis in lymphoma cells through enhanced interaction with FcγRIIIb on neutrophils
- (2009) Tomoaki Nakagawa et al. LEUKEMIA RESEARCH
- Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis
- (2008) Shouvik Dass et al. ARTHRITIS AND RHEUMATISM
- Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody
- (2008) D. M. Goldenberg et al. BLOOD
- Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage Fc RI, Fc RIII, and Fc RIV
- (2008) V. Minard-Colin et al. BLOOD
- Specificity and affinity of human Fc receptors and their polymorphic variants for human IgG subclasses
- (2008) P. Bruhns et al. BLOOD
- Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma
- (2008) Barbara Pro et al. BRITISH JOURNAL OF HAEMATOLOGY
- Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16
- (2008) Christophe de Romeuf et al. BRITISH JOURNAL OF HAEMATOLOGY
- Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities
- (2008) A. Natsume et al. CANCER RESEARCH
- A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma
- (2008) E. Racila et al. CLINICAL CANCER RESEARCH
- Molecular engineering and design of therapeutic antibodies
- (2008) Leonard G Presta CURRENT OPINION IN IMMUNOLOGY
- Complement and cellular cytotoxicity in antibody therapy of cancer
- (2008) Siao-Yi Wang et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- A review of the current use of rituximab in autoimmune diseases
- (2008) Hakan M. Gürcan et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- CD20 Homo-oligomers Physically Associate with the B Cell Antigen Receptor
- (2008) Maria J. Polyak et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Induction of Cytosolic Calcium Flux by CD20 Is Dependent upon B Cell Antigen Receptor Signaling
- (2008) Claire A. Walshe et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimization of antibody binding to Fc RIIa enhances macrophage phagocytosis of tumor cells
- (2008) J. O. Richards et al. MOLECULAR CANCER THERAPEUTICS
- Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors
- (2008) S. L. Sazinsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now